Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide
50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same
dose of Berodual® delivered via an hydrofluoroalkane (HFA) - metered dose inhaler (2 x puffs
) in COPD patients at different inspiratory flow rates.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol Fenoterol, ipratropium drug combination Ipratropium